Tenofovir
Tenofovir-treated HIV associated with increased CKD rate for adults in Tanzania
Adults in Tanzania living with HIV and taking tenofovir have a higher rate of chronic kidney disease vs. those without the viral infection, according to a prospective cohort study.
VIDEO: Simplified screening, treatment strategies critical in HBV
PHILADELPHIA — Paul Kwo, MD, professor of medicine at Stanford University, speaks with Healio about presentations investigating the undertreatment of hepatitis B.
Tenofovir alafenamide maintains virological control in HBV with renal, hepatic impairment
Tenofovir alafenamide was safe and maintained virological response in patients with chronic hepatitis B virus infection and renal or hepatic impairment who switched from tenofovir disoproxil fumarate or other antivirals, according to data.
Sofosbuvir/velpatasvir with tenofovir alafenamide efficacious for HCV, HBV co-infection
BOSTON — After 12 weeks of treatment with sofosbuvir/velpatasvir in combination with tenofovir alafenamide, patients with hepatitis C virus and hepatitis B virus co-infection demonstrated high rates of sustained virologic response.
Older age, high HBsAg levels linked to increased risk for flare after treatment withdrawal
Older age, male sex and increased hepatitis B surface antigen correlated with a higher risk for hepatic flare after nucleos(t)ide analogue withdrawal in patients with chronic HBV, according to data at the EASL Congress.
Study sees possible benefit of tenofovir against COVID-19, but questions remain
An analysis of COVID-19 outcomes among people being treated for HIV or taking PrEP for HIV prevention found that the HIV medication tenofovir was associated with a lower rate of clinical events, suggesting a protective effect.
FDA expands Vemlidy approval for chronic HBV in children aged older than 12 years
The FDA has updated the label indication for 25 mg tenofovir alafenamide for the treatment of chronic hepatitis B virus with compensated liver disease, expanding the patient population to include children aged 12 years older.
No difference in HCC risk between tenofovir, entecavir for chronic HBV infection
There was no clinically meaningful difference in the risk for hepatocellular carcinoma between patients taking tenofovir vs. entecavir to treat chronic hepatitis B virus infection, according to study results published in JAMA Network Open.
High-risk women need higher levels of plasma tenofovir for HIV protection
Women at high risk for HIV need higher levels of plasma tenofovir to prevent infection compared with men, according to data from the largest HIV pharmacokinetics database to date.